Table 7.
I2 | Effectiveness | 0, 95% LCL | 0, 95% UCL | p | |
---|---|---|---|---|---|
Average risk ratio (LAC) | 2.11 | 1.47 | 3.05 | ||
Event rate (LAC) (fixed-effects model) | 0.00 (p=0.671) | 0.68 | 0.50 | 0.78 | 0.002 |
Average risk ratio (OAC) | 1.21 | 0.19 | 7.79 | ||
Event rate (OAC) (random-effects model) | 86.94 (p=0.006) | 0.55 | 0.15 | 0.90 | 0.837 |
Average risk ratio (PAC) | 1.19 | 0.77 | 1.86 | ||
Event rate (PAC) (fixed-effects model) | 48.05 (p=0.146) | 0.50 | 0.48 | 0.64 | 0.123 |
Table 7 shows that studies carried out using the ITT analysis were divided into subgroups according to PPIs with a treatment duration of 7 days. According to this, although the effect magnitudes of studies using the PAC and OAC combinations were found to be insignificant, the effect for the LAC combination was significant.